Galapagos NV, a global biotechnology company, announced the departure of its CFO and COO, Thad Huston, effective as of August 1, 2025. The company expects to announce Huston’s successor in the coming months.

Huston joined Galapagos NV in 2023 from Kite Pharma, Inc., to support Galapagos’ transformation into a cell therapy company. Huston has decided to leave the company and return to the U.S. for personal and professional reasons.

Paul Stoffels, MD, CEO and Chair of the Board of Directors of Galapagos, said, “Over the past two years, Thad has worked on the transformation of Galapagos into a focused cell therapy business leveraging our unique decentralized cell therapy platform to deliver fresh, stem-like early memory CAR-T therapy with a vein-to-vein time of seven days. Thad will remain with the company until August 1, 2025, to ensure a smooth handover of responsibilities.”